Chemomab Therapeutics Ltd (CMMB) FinancialsCMMBChemomab Therapeutics Ltd

Evaluating the bottom line, Chemomab Therapeutics Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -82.17%, provide a clear picture of how effectively CMMB converts its operational activities into shareholder value.

In the context of the broader market, CMMB competes directly with industry leaders such as AKTX and BIVI. With a market capitalization of $19.93M, it holds a significant position in the sector. When comparing efficiency, CMMB's gross margin of N/A stands against AKTX's N/A and BIVI's N/A. Such benchmarking helps identify whether Chemomab Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

Chemomab has shown a significant increase in stock price recently, with a year-to-date change of +51.40%. However, it has consistently reported negative net income over the past quarters, with the latest at -2,165,000 USD for Q2 2026.